Role of protein O-linked N-acetyl-glucosamine in mediating cell function and survival in the cardiovascular system
Open Access
- 15 January 2007
- journal article
- review article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 73 (2), 288-297
- https://doi.org/10.1016/j.cardiores.2006.07.018
Abstract
There is growing recognition that the O-linked attachment of N-acetyl-glucosamine (O-GlcNAc) on serine and threonine residues of nuclear and cytoplasmic proteins is a highly dynamic post-translational modification that plays a key role in signal transduction pathways. Numerous proteins have been identified as targets of O-GlcNAc modifications including kinases, phosphatases, transcription factors, metabolic enzymes, chaperons, and cytoskeletal proteins. Modulation of O-GlcNAc levels has been shown to modify DNA binding, enzyme activity, protein–protein interactions, the half-life of proteins, and subcellular localization. The level of O-GlcNAc is regulated in part by the metabolism of glucose via the hexosamine biosynthesis pathway (HBP), and the metabolic abnormalities associated with insulin resistance and diabetes, such as hyperglycemia, hyperlipidemia, and hyperinsulinemia, are all associated with increased flux through the HBP and elevated O-GlcNAc levels. Increased HBP flux and O-GlcNAc levels have been implicated in the impaired relaxation of isolated cardiomyocytes, blunted response to angiotensin II and phenylephrine, hyperglycemia-induced cardiomyocyte apoptosis, and endothelial and vascular cell dysfunction. In contrast to these adverse effects, recent studies have also shown that O-GlcNAc levels increase in response to acute stress and that this is associated with increased cell survival. Thus, while the relationship between O-GlcNAc levels and cellular function is complex and not well-understood, it is clear that these pathways play a critical role in the regulation of cell function and survival in the cardiovascular system and may be implicated in the adverse effects of metabolic disease on the heart.This publication has 91 references indexed in Scilit:
- Location and characterization of the O-GlcNAcase active siteBiochimica et Biophysica Acta (BBA) - General Subjects, 2006
- Akt1 is dynamically modified with O‐GlcNAc following treatments with PUGNAc and insulin‐like growth factor‐1FEBS Letters, 2006
- The Pathogenesis of Myocardial Fibrosis in the Setting of Diabetic CardiomyopathyJournal of the American College of Cardiology, 2006
- O-GlcNAc modification on IRS-1 and Akt2 by PUGNAc inhibits their phosphorylation and induces insulin resistance in rat primary adipocytesExperimental & Molecular Medicine, 2005
- OGT functions as a catalytic chaperone under heat stress response: a unique defense role of OGT in hyperthermiaBiochemical and Biophysical Research Communications, 2004
- O-GlcNAc a sensor of cellular state: the role of nucleocytoplasmic glycosylation in modulating cellular function in response to nutrition and stressBiochimica et Biophysica Acta (BBA) - General Subjects, 2004
- IncreasedO‐glycosylation of insulin signaling proteins results in their impaired activation and enhanced susceptibility to apoptosis in pancreatic β‐cellsThe FASEB Journal, 2004
- Alloxan is an inhibitor of the enzyme O-linked N-acetylglucosamine transferaseBiochemical and Biophysical Research Communications, 2002
- Glucose Metabolism to Glucosamine Is Necessary for Glucose Stimulation of Transforming Growth Factor-α Gene TranscriptionOnline Journal of Public Health Informatics, 1996
- NIDDM as unfavorable factor to the postinfarctual ventricular function in the elderlyCoronary Artery Disease, 1995